Researchers at NYC Langone Health and Perlmutter Cancer Center have announced a new breakthrough for treating skin cancer.
Researchers say that the combination of an experimental mRNA vaccine and an immunotherapy pembrolizumab dramatically reduced the likelihood of melanoma recurring or causing death by 44% when compared to the immunotherapy by itself.
Study results so far led the United States Food and Drug Administration to grant Breakthrough Therapy Designation to mRNA-4157/V940 in combination with pembrolizumab in February.
News 12 spoke with Dr. Andrew Pecora from the John Theurer Cancer Center Campus about what this could mean for cancer patients.